A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

PHASE3RecruitingINTERVENTIONAL

Enrollment

425

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2026

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

TACE+Camrelizumab+Apatinib mesylate

TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.

PROCEDURE

TACE

TACE Alone.

Trial Locations (1)

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY